



Agency for Healthcare Research and Quality  
Advancing Excellence in Health Care



NATIONAL  
**GUIDELINE**  
CLEARINGHOUSE

## General

### Guideline Title

Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 2: management of posthemorrhagic hydrocephalus in premature infants.

### Bibliographic Source(s)

Mazzola CA, Choudhri AF, Auguste KI, Limbrick DD Jr, Rogido M, Mitchell L, Flannery AM. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 2: Management of posthemorrhagic hydrocephalus in premature infants. J Neurosurg Pediatr. 2014 Nov;14 Suppl 1:8-23. [80 references] [PubMed](#)

### Guideline Status

This is the current release of the guideline.

This guideline meets NGC's 2013 (revised) inclusion criteria.

## Recommendations

### Major Recommendations

The rating schemes used for the strength of the evidence (Class I-III) and the levels of recommendations (Level I-III) are defined at the end of the "Major Recommendations" field.

#### Surgical Temporizing Measures

##### Recommendations

- Ventricular access devices (VADs), external ventricular drains (EVDs), ventriculosubgaleal (VSG) shunts, or lumbar punctures (LPs) are treatment options in the management of posthemorrhagic hydrocephalus (PHH). Clinical judgment is required. Strength of Recommendation: Level II, moderate degree of clinical certainty.
- The evidence demonstrates that VSG shunts reduce the need for daily cerebrospinal fluid (CSF) aspiration compared with VADs. Strength of Recommendation: Level II, moderate degree of clinical certainty.

#### Routine Use of Serial Lumbar Puncture

##### Recommendation

The routine use of serial lumbar puncture (LP) is not recommended to reduce the need for shunt placement or to avoid the progression of hydrocephalus in premature infants. Strength of Recommendation: Level I, high degree of clinical certainty.

## Nonsurgical Temporizing Agents

### Recommendations

- Intraventricular thrombolytic agents including tissue plasminogen activator (tPA), urokinase, or streptokinase are not recommended as methods to reduce the need for shunt placement in premature infants with PHH. Strength of Recommendation: Level I, high clinical certainty
- Acetazolamide and furosemide are not recommended as methods to reduce the need for shunt placement in premature infants with PHH. Strength of Recommendation: Level I, high clinical certainty.

### Timing of Shunt Placement

#### Recommendation

There is insufficient evidence to recommend a specific infant weight or CSF parameter to direct the timing of shunt placement in premature infants with PHH. Clinical judgment is required. Strength of Recommendation: Level III, unclear degree of clinical certainty.

### Endoscopic Third Ventriculostomy

#### Recommendation

There is insufficient evidence to recommend the use of endoscopic third ventriculostomy (ETV) in premature infants with PHH. Strength of Recommendation: Level III, unclear degree of clinical certainty.

### Definitions

#### Levels of Evidence for Primary Research Question<sup>1</sup>

	Therapeutic Studies: Investigating the Results of Treatment	Prognostic Studies: Investigating the Effect of a Patient Characteristic on the Outcome of Disease	Diagnostic Studies: Investigating a Diagnostic Test	Economic and Decision Analyses: Developing an Economic or Decision Model
Class I	<ul style="list-style-type: none"><li>• High quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals</li><li>• Systematic review<sup>2</sup> of Class I RCTs (and study results were homogenous<sup>3</sup>)</li></ul>	<ul style="list-style-type: none"><li>• High quality prospective study<sup>4</sup> (all patients were enrolled at the same point in their disease with <math>\geq 80\%</math> follow-up of enrolled patients)</li><li>• Systematic review<sup>2</sup> of Class I studies</li></ul>	<ul style="list-style-type: none"><li>• Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference "gold" standard)</li><li>• Systematic review<sup>2</sup> of Class I studies</li></ul>	<ul style="list-style-type: none"><li>• Sensible costs and alternatives; values obtained from many studies; with multiway sensitivity analyses</li><li>• Systematic review<sup>2</sup> of Class I studies</li></ul>
Class II	<ul style="list-style-type: none"><li>• Lesser quality RCT (e.g., <math>&lt;80\%</math> follow-up, no blinding, or improper randomization)</li><li>• Prospective<sup>4</sup> comparative study<sup>5</sup></li><li>• Systematic review<sup>2</sup> of Class II studies or Class I studies with inconsistent results</li></ul>	<ul style="list-style-type: none"><li>• Retrospective<sup>6</sup> study</li><li>• Untreated controls from an RCT</li><li>• Lesser quality prospective study (e.g., patients enrolled at different points in their disease or <math>&lt;80\%</math> follow-up)</li><li>• Systematic review<sup>2</sup> of Class II studies</li></ul>	<ul style="list-style-type: none"><li>• Development of diagnostic criteria on consecutive patients (with universally applied reference "gold" standard)</li><li>• Systematic review<sup>2</sup> of Class II studies</li><li>• Study of nonconsecutive patients; without</li></ul>	<ul style="list-style-type: none"><li>• Sensible costs and alternatives; values obtained from limited studies; with multiway sensitivity analyses</li><li>• Systematic review<sup>2</sup> of Level II studies</li></ul>

	Therapeutic Studies Investigating the Results of Treatment comparative study <sup>5</sup> <ul style="list-style-type: none"> <li>• Systematic review<sup>2</sup> of Class II studies</li> </ul>	Prognostic Studies Investigating the Effect of a Patient Characteristic on the Outcome of Disease	Diagnostic Studies Investigating a Diagnostic Test consistently applied "gold" standard <ul style="list-style-type: none"> <li>• Systematic review<sup>2</sup> of Class III studies</li> </ul>	Economic and Decision Analyses. Developing an Economic or Decision Model Analyses based on limited alternatives; and poor costs; and poor estimates <ul style="list-style-type: none"> <li>• Systematic review<sup>2</sup> of Level III studies</li> </ul>
Class III	<ul style="list-style-type: none"> <li>• Case series<sup>8</sup></li> <li>• Expert opinion</li> </ul>	<ul style="list-style-type: none"> <li>• Case series</li> <li>• Expert opinion</li> </ul>	<ul style="list-style-type: none"> <li>• Case control study</li> <li>• Poor reference standard</li> <li>• Expert opinion</li> </ul>	<ul style="list-style-type: none"> <li>• Analyses with no sensitivity analyses</li> <li>• Expert opinion</li> </ul>

RCT = randomized controlled trial

<sup>1</sup>A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.

<sup>2</sup>A combination of results from two or more prior studies.

<sup>3</sup>Studies provided consistent results.

<sup>4</sup>Study was started before the first patient enrolled.

<sup>5</sup>Patients treated one way (e.g., cemented hip arthroplasty) compared with a group of patients treated in another way (e.g., uncemented hip arthroplasty) at the same institution.

<sup>6</sup>The study was started after the first patient enrolled.

<sup>7</sup>Patients identified for the study based on their outcome, called "cases" (e.g., failed total arthroplasty) are compared to those who did not have outcome, called "controls" (e.g., successful total hip arthroplasty).

<sup>8</sup>Patients treated one way with no comparison group of patients treated in another way.

#### Strength of the Recommendations Rating Scheme

The Task Force used methodologies endorsed by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Guidelines Committee to assign a strength category to each recommendation in this review. Linking evidence to recommendations through the use of evidentiary tables has been endorsed by the American Medical Association, the AANS, and the CNS. This process validates and supports the relationship between the strength of evidence and the strength of recommendations. Demonstrating the highest degree of clinical certainty, Class I evidence is used to support recommendations of the strongest type, defined as Level I recommendations. Level II recommendations reflect a moderate degree of clinical certainty and are supported by Class II evidence or a strong consensus of Class III evidence. Level III recommendations denote clinical uncertainty, which is supported by inconclusive or conflicting evidence or expert opinion.

## Clinical Algorithm(s)

None provided

## Scope

## Disease/Condition(s)

Pediatric hydrocephalus

## Guideline Category

Management

Treatment

## Clinical Specialty

Neurological Surgery

Neurology

Pediatrics

## Intended Users

Advanced Practice Nurses

Nurses

Physician Assistants

Physicians

## Guideline Objective(s)

To answer the following question: What are the optimal treatment strategies for posthemorrhagic hydrocephalus (PHH) in premature infants?

## Target Population

Premature infants with posthemorrhagic hydrocephalus (PHH)

## Interventions and Practices Considered

Surgical temporizing measures

- Ventricular access devices (VADs)
- External ventricular drains (EVDs)
- Ventriculosubgaleal (VSG) shunts
- Lumbar punctures (LPs)

Note: The following interventions were considered but not recommended or no recommendation was made:

- Routine use of serial LPs
- Intraventricular thrombolytic agents (tissue plasminogen activator [tPA], urokinase, or streptokinase)
- Acetazolamide and furosemide
- Use of a specific weight or cerebrospinal fluid (CSF) parameter to direct the timing of shunt placement
- Endoscopic third ventriculostomy (ETV)

## Major Outcomes Considered

- Morbidity and mortality rates associated with the surgical treatment of posthemorrhagic hydrocephalus (PHH)
- Need for daily cerebrospinal fluid (CSF) aspiration
- Need for permanent shunt placement
- Neurodevelopmental outcomes
- Infection and other complications

## Methodology

### Methods Used to Collect/Select the Evidence

Hand-searches of Published Literature (Primary Sources)

Hand-searches of Published Literature (Secondary Sources)

Searches of Electronic Databases

### Description of Methods Used to Collect/Select the Evidence

#### General Search Strategy

##### Literature Search

The Task Force worked with a research librarian and methodologist to assist with the formulation of search terms and strategies used to search the US National Library of Medicine PubMed/MEDLINE database and the Cochrane Database of Systematic Reviews for relevant literature published between January 1966 and March 2012.

Four to five Task Force members used the article inclusion/exclusion criteria described below to screen abstracts and provide a list of relevant articles for a full-text review. Each Task Force member was blinded to the lists of abstracts provided by others. Staff compiled all lists together for review and final approval by all Task Force members.

The searches were supplemented with manual screenings of bibliographies from all retrieved articles. In addition, the bibliographies of potentially relevant systematic reviews were screened for potentially relevant articles. All literature identified either by searches of the electronic database or by manual searches were subject to the article inclusion/exclusion criteria listed below. Specific search strategies used by Task Force members are provided below.

##### Article Inclusion/Exclusion Criteria

Articles were retrieved and included as evidence to support the topics discussed in this review if they met specific inclusion/exclusion criteria. These criteria were also applied to articles provided by Task Force members who supplemented the electronic database searches with articles obtained from manual searches of bibliographies from the original articles. To reduce bias, the criteria were specified before conducting the literature searches. For the purposes of the systematic review and guidelines, articles that did not meet the following criteria were *not* deemed evidence and were not considered as potential evidence to support the topics and clinical recommendations.

To be included in the review, an article had to meet the following criteria:

- Studies that combined results in patients (younger than 18 years of age) who had congenital and acquired hydrocephalus with results in patients with "normal" pressure hydrocephalus were excluded if the study enrolled fewer than 80% of the target patient population.
- Studies that enrolled mixed patient populations were included only if separate results were reported for the target population. The results of the target population were the only results considered as evidence to support our recommendations.
- The study was a full article report of a clinical study.
- The study was not a meeting abstract, editorial, letter, or a commentary.
- Prospective case series had to report baseline values.
- Case series studies with nonconsecutive enrollment of patients were excluded.
- Studies had to have appeared in a peer-reviewed publication or a registry report.
- Studies had to enroll at least 10 patients for each distinct outcome that was measured. If a comparative study, a minimum enrollment of five patients per treatment arm for each outcome was necessary.

- The study involved humans.
- The study was published in or after 1966.
- The study presented results quantitatively.
- The study did not involve "in vitro" or "biomechanical" data or results obtained in cadavers.
- The study was published in English.
- Papers reporting the results of systematic reviews, meta-analyses, or guidelines developed by others were excluded.

Articles presenting systematic reviews or meta-analyses conducted by others, as well as guidelines developed by others, were not included as evidence to support this review due to differences in inclusion/exclusion criteria between those specified in such articles and those established by the Task Force. Although such articles were not included as evidence to support the review, they were recalled for full-text review so that the Task Force could conduct manual searches of the articles' bibliographies.

#### Specific Search Strategy for This Guideline

Both the US National Library of Medicine and the Cochrane Database of Systematic Reviews were queried using medical subject headings (MeSH) and key words relevant to posthemorrhagic hydrocephalus (PHH).

#### Key Words

The following key words were used in this study: (((preterm[All Fields] AND Intraventricular[All Fields] AND ("haemorrhage"[All Fields] OR "hemorrhage"[MeSH Terms] OR "hemorrhage"[All Fields])) OR (("infant, premature" [MeSH Terms] OR ("infant"[All Fields] AND "premature" [All Fields]) OR "premature infant"[All Fields] OR ("preterm[All Fields] AND "infant"[All Fields]) OR "preterm infant"[All Fields]) AND ("hydrocephalus"[MeSH Terms] OR "hydrocephalus" [All Fields]))) OR ((preterm[All Fields] AND ("heart ventricles"[MeSH Terms] OR ("heart" [All Fields] AND "ventricles"[All Fields]) OR "heart ventricles"[All Fields] OR "ventricular"[All Fields]) AND reservoir[All Fields])) AND shunt[All Fields].

#### Strategy

Two hundred thirteen abstracts were reviewed, after which 98 publications that met the inclusion criteria were selected. In addition to the overall inclusion/exclusion criteria specified above, additional inclusion criteria included studies in which infants younger than 12 months with all forms of hydrocephalus—both congenital and acquired—were evaluated to ensure that the maximum number of studies were reviewed. The analysis focused on studies evaluating infants with PHH because of the treatment strategies and challenges unique to this patient population.

As a result of the US National Library of Medicine's search engine functionalities, additional search terms (heart ventricles) not relevant to topics addressed in this chapter were added to the search strategy. Although these search terms remained in the search strategy, the Task Force did not recall any references retrieved using them for full-text review. Those references were excluded because they were not relevant to the overall scope of this project or the patient population addressed in this chapter and, therefore, did not meet the article inclusion criteria specified above.

Following an evidentiary analysis and a review of the 98 full-text articles, 68 publications were accepted for inclusion in the evidentiary table and 30 publications were excluded.

## Number of Source Documents

Of the 98 full-text articles selected for review, 30 full-text publications were rejected and only 68 articles were used to construct the evidentiary table. See Fig. 1 in the original guideline document for the flowchart showing the process involved in identifying relevant literature.

## Methods Used to Assess the Quality and Strength of the Evidence

Weighting According to a Rating Scheme (Scheme Given)

## Rating Scheme for the Strength of the Evidence

Levels of Evidence for Primary Research Question<sup>1</sup>

	Therapeutic Studies: Investigating the Results of Treatment	Prognostic Studies: Investigating the Effect of a Patient Characteristic on the Outcome of Disease	Diagnostic Studies: Investigating a Diagnostic Test	Economic and Decision Analyses: Developing an Economic or Decision Model
Class I	<ul style="list-style-type: none"> <li>• High quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals</li> <li>• Systematic review<sup>2</sup> of Class I RCTs (and study results were homogenous<sup>3</sup>)</li> </ul>	<ul style="list-style-type: none"> <li>• High quality prospective study<sup>4</sup> (all patients were enrolled at the same point in their disease with <math>\geq 80\%</math> follow-up of enrolled patients)</li> <li>• Systematic review<sup>2</sup> of Class I studies</li> </ul>	<ul style="list-style-type: none"> <li>• Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference "gold" standard)</li> <li>• Systematic review<sup>2</sup> of Class I studies</li> </ul>	<ul style="list-style-type: none"> <li>• Sensible costs and alternatives; values obtained from many studies; with multiway sensitivity analyses</li> <li>• Systematic review<sup>2</sup> of Class I studies</li> </ul>
Class II	<ul style="list-style-type: none"> <li>• Lesser quality RCT (e.g., <math>&lt;80\%</math> follow-up, no blinding, or improper randomization)</li> <li>• Prospective<sup>4</sup> comparative study<sup>5</sup></li> <li>• Systematic review<sup>2</sup> of Class II studies or Class I studies with inconsistent results</li> <li>• Case control study<sup>7</sup></li> <li>• Retrospective<sup>6</sup> comparative study<sup>5</sup></li> <li>• Systematic review<sup>2</sup> of Class II studies</li> </ul>	<ul style="list-style-type: none"> <li>• Retrospective<sup>6</sup> study</li> <li>• Untreated controls from an RCT</li> <li>• Lesser quality prospective study (e.g., patients enrolled at different points in their disease or <math>&lt;80\%</math> follow-up)</li> <li>• Systematic review<sup>2</sup> of Class II studies</li> <li>• Case control study<sup>7</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Development of diagnostic criteria on consecutive patients (with universally applied reference "gold" standard)</li> <li>• Systematic review<sup>2</sup> of Class II studies</li> <li>• Study of nonconsecutive patients; without consistently applied "gold" standard</li> <li>• Systematic review<sup>2</sup> of Class III studies</li> </ul>	<ul style="list-style-type: none"> <li>• Sensible costs and alternatives; values obtained from limited studies; with multiway sensitivity analyses</li> <li>• Systematic review<sup>2</sup> of Level II studies</li> <li>• Analyses based on limited alternatives and costs; and poor estimates</li> <li>• Systematic review<sup>2</sup> of Level III studies</li> </ul>
Class III	<ul style="list-style-type: none"> <li>• Case series<sup>8</sup></li> <li>• Expert opinion</li> </ul>	<ul style="list-style-type: none"> <li>• Case series</li> <li>• Expert opinion</li> </ul>	<ul style="list-style-type: none"> <li>• Case control study</li> <li>• Poor reference standard</li> <li>• Expert opinion</li> </ul>	<ul style="list-style-type: none"> <li>• Analyses with no sensitivity analyses</li> <li>• Expert opinion</li> </ul>

RCT = randomized controlled trial

<sup>1</sup>A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.

<sup>2</sup>A combination of results from two or more prior studies.

<sup>3</sup>Studies provided consistent results.

<sup>4</sup>Study was started before the first patient enrolled.

<sup>5</sup>Patients treated one way (e.g., cemented hip arthroplasty) compared with a group of patients treated in another way (e.g., uncemented hip arthroplasty) at the same institution.

<sup>6</sup>The study was started after the first patient enrolled.

<sup>7</sup>Patients identified for the study based on their outcome, called "cases" (e.g., failed total arthroplasty) are compared to those who did not have outcome, called "controls" (e.g., successful total hip arthroplasty).

<sup>8</sup>Patients treated one way with no comparison group of patients treated in another way.

## Methods Used to Analyze the Evidence

Review of Published Meta-Analyses

Systematic Review with Evidence Tables

## Description of the Methods Used to Analyze the Evidence

The quality of evidence was rated using an evidence hierarchy developed by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Guidelines Committee for each of the four different study types: therapeutic, diagnostic, prognostic, and clinical assessment (see the "Rating Scheme for the Strength of the Evidence" field).

The evidentiary table was assembled linking recommendations to the strength of the evidence.

## Methods Used to Formulate the Recommendations

Expert Consensus (Nominal Group Technique)

## Description of Methods Used to Formulate the Recommendations

The recommendations contained in this guideline deliberately eschew the use of expert opinion, relying strictly on information available in the literature. Studies have reported that expert opinions may not use evaluable evidence, if the papers containing that evidence do not support the "expert" point of view. Throughout the development of these guidelines, the Task Force used evidence-based methodologies and adhered to strict criteria that had been defined a priori as specified by the Institute of Medicine's standards for conducting systematic reviews and clinical evidence-based guidelines.

This effort was begun by a small study group that convened at the Pediatric Section Annual Meeting in Austin, Texas, in 2011. At that time the basic topics were considered, and over the course of several months these were further refined. Members of the Task Force involved in the creation of this document were recruited from a variety of institutions and subspecialty disciplines in an effort to have as broad a representation of opinions and expertise as possible.

The Task Force followed protocols established by the Joint Guidelines Committee (JGC) of the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS). A conscientious effort was also made to be sure that conflict of interest was avoided. Members who had published extensively in certain areas were mindfully assigned to evaluate evidence in other topics. Every effort was made to ensure that the work product would be transparent and trustworthy.

### Methods

#### Process Overview

The Task Force and the Pediatric Section of the AANS/CNS conducted a systematic review of the literature relevant to the management of hydrocephalus in infants and children. Additional details of the systematic review are provided below. During the development process, the panel participated in a series of conference calls and meetings. Multiple iterations of the written review were conducted by individuals in the Task Force



and various AANS/CNS committees.

### Selection of Clinical Topics

The goals of this effort were to discern the most effective strategies for a variety of hydrocephalus-related problems, including acquired hydrocephalus of the premature neonate. The Task Force also considered the use of technical adjuvants such as antibiotic-impregnated catheters, endoscopic placement of shunt catheters, electromagnetic guidance for shunt catheter placement, and ultrasound guidance for shunt catheter placement. It was hoped that these adjuvants would lead to improvements in outcome and a reduction in the frequency of revision.

Complications associated with ventriculoperitoneal shunts and endoscopic third ventriculostomies are known, and these interventions' effects and long-term successes are useful to evaluate. Complications associated with infection are of particular significance. Therefore, the prevention and treatment of infection occupies a significant portion of the hydrocephalus literature. Finally, the correlation of ventricle size to outcome in a child is a source of great interest as an indicator of the success of the intervention.

Following the identification of hydrocephalus-related problems, the Task Force developed preliminary recommendations that were formatted similarly to the PICO (patients, interventions, comparisons, and outcomes) formula to aid in the determination of the overall scope of the review and the terminology used to formulate the literature search strategies.

### Voting on the Recommendations

The Task Force used a structured voting technique to finalize and approve the final recommendations, language, and strength of the recommendations presented in this review. The voting technique is referred to as the "nominal group technique." This technique includes up to 3 rounds of voting using secret ballots to ensure that each Task Force member is blinded to the responses of other Task Force members. All the recommendations in this review were approved following the first round of voting and no further discussion was needed to finalize the recommendations. During the course of editing and finalizing the document, changes were made to allow recommendations to conform to the rules of evidence and language as described earlier. When this occurred, the changes were reviewed and approved by the group.

See Fig. 1 in the methodology document (see the "Availability of Companion Documents" field) for an outline of the key steps in the process of developing these clinical practice guidelines.

## Rating Scheme for the Strength of the Recommendations

### Strength of the Recommendations Rating Scheme

The Task Force used methodologies endorsed by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Guidelines Committee to assign a strength category to each recommendation in this review. Linking evidence to recommendations through the use of evidentiary tables has been endorsed by the American Medical Association, the AANS, and the CNS. This process validates and supports the relationship between the strength of evidence and the strength of recommendations. Demonstrating the highest degree of clinical certainty, Class I evidence is used to support recommendations of the strongest type, defined as Level I recommendations. Level II recommendations reflect a moderate degree of clinical certainty and are supported by Class II evidence or a strong consensus of Class III evidence. Level III recommendations denote clinical uncertainty, which is supported by inconclusive or conflicting evidence or expert opinion.

## Cost Analysis

A formal cost analysis was not performed and published cost analyses were not reviewed.

## Method of Guideline Validation

### Internal Peer Review

## Description of Method of Guideline Validation

### Guideline Panel Consensus and Practice Guideline Approval Process

Topic subtask forces were created from the larger Task Force. Each subtask force took part in the literature selection, review of the literature,

creation of the evidence tables, and creation and editing of the final review. The final draft review was then circulated to the entire Task Force for feedback, discussion, and, ultimately, approval.

Following Task Force approval, the completed systematic review was presented to the Joint Guidelines Committee (JGC) of the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) for consideration and recommendation of endorsement on behalf of the CNS Executive Committee and the AANS Board of Directors. As part of the evaluation process, the JGC reviewers could provide input on the content and methodologies used to create the systematic review.

## Evidence Supporting the Recommendations

### Type of Evidence Supporting the Recommendations

The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).

## Benefits/Harms of Implementing the Guideline Recommendations

### Potential Benefits

Use of optimal treatment strategies for posthemorrhagic hydrocephalus (PHH) in premature infants to reduce morbidity and mortality

### Potential Harms

Shunt failure or infection

## Qualifying Statements

### Qualifying Statements

- This clinical systematic review of and evidence-based guidelines for the treatment of pediatric hydrocephalus were developed by a physician volunteer task force. The articles contained therein are provided as an educational tool based on an assessment of current scientific and clinical information as well as accepted approaches to treatment. They are not intended to be a fixed protocol because some patients may require more or less treatment. Patient care and treatment should always be based on a clinician's independent medical judgment given individual clinical circumstances. The information in the guidelines reflects the current state of knowledge at the time of the project's completion. The presentations are designed to provide an accurate review of the subject matter that is covered. These guidelines are disseminated with the understanding that the recommendations of the authors and consultants who have collaborated in their development are not meant to replace individualized care and treatment advice from patients' physicians. If medical advice or assistance is required, the services of a competent physician should be sought.
- The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of each patient's particular situation and on the basis of existing resources.

## Implementation of the Guideline

### Description of Implementation Strategy

An implementation strategy was not provided.

## Implementation Tools

### Resources

For information about availability, see the *Availability of Companion Documents* and *Patient Resources* fields below.

## Institute of Medicine (IOM) National Healthcare Quality Report Categories

### IOM Care Need

Getting Better

Living with Illness

### IOM Domain

Effectiveness

Safety

## Identifying Information and Availability

### Bibliographic Source(s)

Mazzola CA, Choudhri AF, Auguste KI, Limbrick DD Jr, Rogido M, Mitchell L, Flannery AM. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 2: Management of posthemorrhagic hydrocephalus in premature infants. *J Neurosurg Pediatr*. 2014 Nov;14 Suppl 1:8-23. [80 references] [PubMed](#)

### Adaptation

Not applicable: The guideline was not adapted from another source.

### Date Released

2014 Nov

### Guideline Developer(s)

American Association of Neurological Surgeons - Medical Specialty Society

Congress of Neurological Surgeons - Professional Association

### Source(s) of Funding

The systematic review and evidence-based guidelines were funded exclusively by the Congress of Neurological Surgeons (CNS) and American Association of Neurological Surgeons (AANS) Pediatric Section, which received no funding from outside commercial sources to support the development of this document.

Development of this review was editorially independent from the funding agencies. The funding agencies' review of these guideline papers, following Joint Guidelines Committee (JGC) approval but prior to submission for publication, was limited to whether to endorse or reject the body of work.

## Guideline Committee

Pediatric Hydrocephalus Systematic Review and Evidence-Based Guidelines Task Force

## Composition of Group That Authored the Guideline

*Authors:* Catherine A. Mazzola, MD, Division of Pediatric Neurological Surgery, Goryeb Children's Hospital, Morristown, New Jersey; Asim F. Choudhri, MD, Departments of Radiology and Neurosurgery, University of Tennessee Health Science Center, Le Bonheur Neuroscience Institute, Le Bonheur Children's Hospital, Memphis, Tennessee; Kurtis I. Auguste, MD, Department of Neurosurgery, University of California, San Francisco, California; David D. Limbrick Jr., MD, PhD, Division of Pediatric Neurosurgery, St. Louis Children's Hospital, St. Louis, Missouri; Marta Rogido, MD, Division of Neonatology, Department of Pediatrics, Goryeb Children's Hospital, Morristown, Rutgers New Jersey Medical School, Newark, New Jersey; Laura Mitchell, MA, Congress of Neurological Surgeons, Schaumburg, Illinois; Ann Marie Flannery, MD, Department of Neurological Surgery, Saint Louis University, St. Louis, Missouri

## Financial Disclosures/Conflicts of Interest

### Disclosure

Dr. Limbrick receives research funding from the National Institute of Neurological Disorders and Stroke.

### Conflict(s) of Interest

None. All Pediatric Hydrocephalus Systematic Review and Evidence-Based Guidelines Task Force members declared any potential conflicts of interest prior to beginning work on this systematic review and evidence-based guidelines.

## Guideline Status

This is the current release of the guideline.

This guideline meets NGC's 2013 (revised) inclusion criteria.

## Guideline Availability

Available from the [Journal of Neurosurgery: Pediatrics Web site](#) .

## Availability of Companion Documents

The following are available:

- Flannery AM, Mazzola CA, Klimo P Jr, Duhaime AC, Baird LC, Tamber MS, Limbrick DD Jr, Nikas DC, Kemp J, Post AF, Auguste KI, Choudhri AF, Mitchell LS, Buffa D. Foreword: pediatric hydrocephalus: systematic literature review and evidence-based guidelines. *J Neurosurg Pediatr*; 2014 Nov;14 Suppl 1:1-2. Available from the [Journal of Neurosurgery: Pediatrics Web site](#) .
- Flannery AM, Mitchell L. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 1: introduction and methodology. *J Neurosurg Pediatr*; 2014 Nov;14 Suppl 1:3-7. Available from the [Journal of Neurosurgery: Pediatrics Web site](#) .
- JNS pediatrics supplement: pediatric hydrocephalus systematic literature review and evidence-based guidelines. Podcast. 2014 Nov 1. Available from the [Journal of Neurosurgery Web site](#) .

- Guideline development methodology: endorsed by the American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS), and the AANS/CNS Joint Guideline Committee. 2012 Feb. 12 p. Available from the [Congress of Neurological Surgeons Web site](#) .

## Patient Resources

None available

## NGC Status

This NGC summary was completed by ECRI Institute on September 17, 2015. The information was not verified by the guideline developer.

## Copyright Statement

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

## Disclaimer

### NGC Disclaimer

The National Guideline Clearinghouse<sup>®</sup> (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion-criteria.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.